Detecting asymptomatic recurrence after radical cystectomy contributes to better prognosis in patients with muscle-invasive bladder cancer

被引:0
作者
Ayumu Kusaka
Shingo Hatakeyama
Shogo Hosogoe
Itsuto Hamano
Hiromichi Iwamura
Naoki Fujita
Ken Fukushi
Takuma Narita
Hayato Yamamoto
Yuki Tobisawa
Tohru Yoneyama
Takahiro Yoneyama
Yasuhiro Hashimoto
Takuya Koie
Hiroyuki Ito
Kazuaki Yoshikawa
Toshiaki Kawaguchi
Chikara Ohyama
机构
[1] Hirosaki University Graduate School of Medicine,Department of Urology
[2] Hirosaki University Graduate School of Medicine,Department of Advanced Transplant and Regenerative Medicine
[3] Aomori Rosai Hospital,Department of Urology
[4] Mutsu General Hospital,Department of Urology
[5] Aomori Prefectural Central Hospital,Department of Urology
来源
Medical Oncology | 2017年 / 34卷
关键词
Radical cystectomy; Recurrence; Asymptomatic; Symptomatic; Survival;
D O I
暂无
中图分类号
学科分类号
摘要
The prognostic benefit of oncological follow-up to detect asymptomatic recurrence after radical cystectomy (RC) remains unclear. We aimed to assess whether routine follow-up to detect asymptomatic recurrence after RC improves patient survival. We retrospectively analyzed 581 RC cases for muscle-invasive bladder cancer at four hospitals between May 1996 and February 2017. All patients had regular follow-up examinations with urine cytology, blood biochemical tests, and computed tomography after RC. We investigated the first site and date of tumor recurrence. Overall survival in patients with recurrence stratified by the mode of recurrence (asymptomatic group vs. symptomatic group) was estimated using the Kaplan–Meier method with the log-rank test. Cox proportional hazards regression analysis via inverse probability of treatment weighting (IPTW) was used to evaluate the impact of the mode of diagnosing recurrence on survival. Of the 581 patients, 175 experienced relapse. Among those, 12 without adequate data were excluded. Of the remaining 163 patients, 76 (47%) were asymptomatic and 87 (53%) were symptomatic at the time of diagnosis. The most common recurrence site and symptom were lymph nodes (47%) and pain (53%), respectively. Time of overall survival after RC and from recurrence to death was significantly longer in the asymptomatic group than in the symptomatic group. A multivariate Cox regression analysis using IPTW showed that in the patients with symptomatic recurrence was an independent risk factor for overall survival after RC and survival from recurrence to death. Routine oncological follow-up for detection of asymptomatic recurrence contributes to a better prognosis after RC.
引用
收藏
相关论文
共 123 条
[11]  
Mansson W(2011)A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy Lancet Oncol 12 211-214
[12]  
Mills RD(2012)Minimum incision endoscopic radical cystectomy in patients with malignant tumors of the urinary bladder: clinical and oncological outcomes at a single institution Eur J Surg Oncol 38 1101-1105
[13]  
Stein JP(2006)Experience and functional outcome of modified ileal neobladder in 95 patients Int J Urol 13 1175-1179
[14]  
Lieskovsky G(2010)Uterus-, fallopian tube-, ovary-, and vagina-sparing cystectomy followed by U-shaped ileal neobladder construction for female bladder cancer patients: oncological and functional outcomes Urology 75 1499-1503
[15]  
Cote R(1950)Bladder substitution after pelvic evisceration Surg Clin North Am 30 1511-1521
[16]  
Groshen S(1977)A new technique for catheterless cutaneous ureterostomy J Urol 117 276-278
[17]  
Feng AC(2015)Evaluation of current surveillance guidelines following radical cystectomy and proposal of a novel risk-based approach Urol Oncol 33 e1-e8
[18]  
Boyd S(2015)Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies Stat Med 34 3661-3679
[19]  
Yafi FA(1995)Cost of patient follow-up after potentially curative colorectal cancer treatment JAMA 273 1837-1841
[20]  
Aprikian AG(2006)Follow-up after primary therapy for endometrial cancer: a systematic review Gynecol Oncol 101 520-529